🇺🇸 FDA
Pipeline program

BGS649

MBGS206

Phase 2 small_molecule completed

Quick answer

BGS649 for Hypogonadotropic Hypogonadism is a Phase 2 program (small_molecule) at Mereo BioPharma Group plc with 2 ClinicalTrials.gov record(s).

Program details

Company
Mereo BioPharma Group plc
Indication
Hypogonadotropic Hypogonadism
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials